Biofilm formation by Escherichia coli presents a major challenge in the clinical settings,
resulting in persistent infections and treatment failures. These bacterial communities, protected
by a matrix, resist antibiotics and immune responses, thus causing a prolonged challenge to
treat such infections. Developing effective strategies against E. coli biofilms is crucial for
improving the patient outcomes and reducing the burden on the healthcare systems. This study
aimed to extract, purify, and characterize mannan from Saccharomyces cerevisiae, then its
antibiofilm activity was evaluated against the multi-drug resistant E. coli (MDR-E. coli)
isolates obtained from various clinical sources (i.e., urine, stool, wound, and catheter). Using a
standardized protocol with slight modifications, the crude mannan extraction yielded 37.6 %,
and subsequent purification achieved an efficiency of 99.6 %. Characterization assays of the
purified mannan included FT-IR; FE-SEM, carbohydrate content estimation, solubility, and
melting point tests, which revealed the presence of α-1,6 and α-1,2 linked sugars; crystalline
nature, high porosity (80 %) carbohydrate content, high solubility in water, and a melting point
of 248 °C. The purified mannan exhibited a substantial ability to inhibit biofilm formation
(37.50 %) and degrade the existing MDR-E. coli biofilms (37.43 %). These findings
underscore the potential of S. cerevisiae mannan as an effective antibiofilm agent for the
clinical applications. Further exploration and optimization of the mannan's therapeutic
potential are essential to fully leverage its efficacy in combating the biofilm-associated
infections caused by MDR-E. coli.